Results 271 to 280 of about 305,984 (384)

Yield of Genetic Testing in Pediatric Cardiomyopathies: Implications for Novel Therapeutic Options. [PDF]

Mol Genet Genomic Med
Ballerini A, Girolami F, Gozzini A, Passantino S, Zampieri M, Marchi A, Tomberli A, Calabri GB, Spaziani G, Porcedda G, Bennati E, Favilli S, Olivotto I.   +12 more
europepmc   +1 more source

Classification, Epidemiology, and Global Burden of Cardiomyopathies.

Circulation Research, 2017
W. McKenna, B. Maron, G. Thiene
semanticscholar   +1 more source

Heart failure in two male patients with late‐onset Fabry mutation (IVS4 + 919G > A)

ESC Heart Failure, Volume 12, Issue 2, Page 1508-1513, April 2025.
Xufei Yang, Chunlan Deng, Xiaogang Guo, Hui Yan   +3 more
wiley   +1 more source

Epidemiology of hospitalized heart failure in France based on national data over 10 years, 2012–2022

ESC Heart Failure, Volume 12, Issue 2, Page 1283-1294, April 2025.
Abstract Aims We aim to describe the incidence of HF hospitalization in France in the post‐pandemic era, the prevalence of HF cases and patients' characteristics, management and outcomes while focusing on sex, age and socio‐economic differences and to analyse time‐trends between 2012 and 2022.
Valérie Olié, Richard Isnard, Françoise Pousset, Clémence Grave, Jacques Blacher, Amélie Gabet   +5 more
wiley   +1 more source

From Rare Genetic Variants to Polygenic Risk: Understanding the Genetic Basis of Cardiomyopathies. [PDF]

J Cardiovasc Dev Dis
Garcia-Ruano AB, Sola-Garcia E, Martin-Istillarty M, Urbano-Moral JA.   +3 more
europepmc   +1 more source

A Case of Takotsubo Cardiomyopathy Complicated by Transient Cataplectic Attack of Upper Limb [PDF]

, 2015
Joh Akama, Atsushi Kobayashi, Yusuke Kimishima, Takashi Kaneshiro, Nobuo Sakamoto, Koichi Sugimoto, Hitoshi Suzuki, Shu‐ichi Saitoh, Yasuchika Takeishi   +8 more
openalex   +1 more source

Considerations for drug trials in hypertrophic cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 1095-1112, April 2025.
Abstract Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition with potentially serious manifestations. Management has traditionally comprised therapies to palliate symptoms and implantable cardioverter‐defibrillators to prevent sudden cardiac death. The need for disease‐modifying therapies has been recognized for decades.
John P. Farrant, Matthias Schmitt, Anna B. Reid, Clifford J. Garratt, William G. Newman, Aneil Malhotra, Rhys Beynon, Masliza Mahmod, Betty Raman, Robert M. Cooper, Dana Dawson, Thomas Green, Sanjay K. Prasad, Anvesha Singh, Susanna Dodd, Hugh Watkins, Stefan Neubauer, Christopher A. Miller   +17 more
wiley   +1 more source

Echocardiographic Features of Cardiomyopathies: A Comprehensive Review. [PDF]

Echocardiography
Al-Naami GH.
europepmc   +1 more source

Amyloid Cardiomyopathy ∗

Journal of the American College of Cardiology, 2016
Merrill D, Benson, Noel R, Dasgupta
openaire   +2 more sources

Association of BMI with adherence and outcome in heart failure patients treated with wearable cardioverter defibrillator

ESC Heart Failure, Volume 12, Issue 2, Page 1295-1303, April 2025.
Abstract Background Obesity is a known risk factor for cardiovascular disease (CVD), yet an ‘obesity paradox’ has been observed in various CVD contexts. The impact of obesity on heart failure (HF) patients treated with a wearable cardioverter‐defibrillator (WCD) remains underexplored.
Mohammad Abumayyaleh, Katharina Koepsel, Julia W. Erath, Thomas Kuntz, Norbert Klein, Boldizsar Kovacs, Firat Duru, Ardan M. Saguner, Christian Blockhaus, Dong‐In Shin, Fabienne Kreimer, Michael Gotzmann, Hendrik Lapp, Thomas Beiert, Assem Aweimer, Andreas Mügge, Christel Weiß, Ibrahim El‐Battrawy, Ibrahim Akin   +18 more
wiley   +1 more source